Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVW2 | ISIN: US1374041093 | Ticker-Symbol:
NASDAQ
24.04.25
21:59 Uhr
4,995 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANDEL THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CANDEL THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CANDEL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCandel Therapeutics to Present Prostate Cancer Trial Data4
MiCandel Therapeutics wird Daten zu Prostatakrebs-Studie präsentieren4
MiCandel Therapeutics, Inc. - 8-K, Current Report3
MiCandel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 202567NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
► Artikel lesen
01.04.Candel's Phase I Trial Data For CAN-2409 In High-grade Glioma Published In Neuro-Oncology1
01.04.Candel reports positive phase 1b glioma trial results1
01.04.Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients106NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
► Artikel lesen
27.03.Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients2
CANDEL THERAPEUTICS Aktie jetzt für 0€ handeln
27.03.Candel's lung cancer survival data light path toward pivotal trial in subpopulation3
18.03.Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board1
17.03.H.C. Wainwright maintains Buy on Candel Therapeutics stock4
13.03.Candel Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
13.03.Candel Therapeutics, Inc. - 10-K, Annual Report2
13.03.Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights125Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final...
► Artikel lesen
13.03.Candel Therapeutics, Inc. - 8-K, Current Report3
25.02.Candel stock plunges 20% following Phase 2 data release13
25.02.Candel Therapeutics stock rises on positive trial data 5
25.02.Candel Therapeutics Aktie steigt nach positiven Studiendaten5
25.02.Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer146Positive final survival data after additional follow-up showed notable improvement in estimated median overall survival of 31.4 months after experimental treatment with CAN-2409 versus only 12.5 months...
► Artikel lesen
25.02.Candel Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1